Click here to listen.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in […]<\/p>\n","protected":false},"author":2,"featured_media":8909,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[56,61,62],"class_list":["post-8908","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-podcasts","tag-neurology","tag-parkinsons-disease","tag-podcast"],"acf":[],"yoast_head":"\n
Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app<\/title>\n<meta name=\"description\" content=\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app\" \/>\n<meta property=\"og:description\" content=\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"榴莲社区app\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-25T18:18:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-16T22:35:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"榴莲社区app Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"榴莲社区app Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\",\"url\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\",\"name\":\"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app\",\"isPartOf\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"datePublished\":\"2024-04-25T18:18:39+00:00\",\"dateModified\":\"2024-05-16T22:35:50+00:00\",\"author\":{\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\"},\"description\":\"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage\",\"url\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"contentUrl\":\"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg\",\"width\":1280,\"height\":720,\"caption\":\"multicolor title graphic for cell & gene the podcast featuring 榴莲社区app Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.bluerocktx.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics’ Parkinson’s Disease Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.bluerocktx.com\/#website\",\"url\":\"https:\/\/www.bluerocktx.com\/\",\"name\":\"榴莲社区app\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.bluerocktx.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057\",\"name\":\"榴莲社区app Therapeutics\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g\",\"caption\":\"榴莲社区app Therapeutics\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app","description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","og_locale":"en_US","og_type":"article","og_title":"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app","og_description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","og_url":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","og_site_name":"榴莲社区app","article_published_time":"2024-04-25T18:18:39+00:00","article_modified_time":"2024-05-16T22:35:50+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","type":"image\/jpeg"}],"author":"榴莲社区app Therapeutics","twitter_card":"summary_large_image","twitter_misc":{"Written by":"榴莲社区app Therapeutics","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","url":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/","name":"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics' Parkinson's Disease Trial - 榴莲社区app","isPartOf":{"@id":"https:\/\/www.bluerocktx.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","datePublished":"2024-04-25T18:18:39+00:00","dateModified":"2024-05-16T22:35:50+00:00","author":{"@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057"},"description":"Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company's phase I clinical trial for Parkinson\u2019s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells' (iPSCs) play in the trial, and they also discuss the company's investigational cell therapy, bemdaneprocel.","breadcrumb":{"@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#primaryimage","url":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","contentUrl":"https:\/\/www.bluerocktx.com\/wp-content\/uploads\/2024\/04\/23_12_CGPodcast_1280x720_Ep74.jpg","width":1280,"height":720,"caption":"multicolor title graphic for cell & gene the podcast featuring 榴莲社区app Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/www.bluerocktx.com\/cell-gene-the-podcast-inside-bluerock-therapeutics-parkinsons-disease-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.bluerocktx.com\/"},{"@type":"ListItem","position":2,"name":"Cell & Gene The Podcast: Inside 榴莲社区app Therapeutics’ Parkinson’s Disease Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.bluerocktx.com\/#website","url":"https:\/\/www.bluerocktx.com\/","name":"榴莲社区app","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.bluerocktx.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/7bce67a9ee8dcf888329288a28761057","name":"榴莲社区app Therapeutics","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.bluerocktx.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/154b53ac9f1feafa6f14d0efa17a4fdb?s=96&d=mm&r=g","caption":"榴莲社区app Therapeutics"}}]}},"_links":{"self":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908"}],"collection":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/comments?post=8908"}],"version-history":[{"count":3,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908\/revisions"}],"predecessor-version":[{"id":8939,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/posts\/8908\/revisions\/8939"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media\/8909"}],"wp:attachment":[{"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/media?parent=8908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/categories?post=8908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bluerocktx.com\/wp-json\/wp\/v2\/tags?post=8908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}